Semaglutide and diabetic retinopathy: an OHDSI network study

IntroductionSemaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications including proliferative DR (PDR) and diabetic macular edema (DME). The purpose of this s...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMJ open diabetes research & care Ročník 13; číslo 6; s. e005424
Hlavní autori:	Cai, Cindy Xinji, Nishimura, Akihiko, Baxter, Sally, Goetz, Kerry, Hribar, Michelle, Toy, Brian, Barkmeier, Andrew, Wang, Sophia, Swaminathan, Swarup, Flowers, Alexis, Brown, Eric, Xu, Benjamin, Chen, John, Chen, Aiyin, Leng, Theodore, Boland, Michael, Alshammari, Thamir, Bu, Fan, Falconer, Thomas, Martin, Benjamin, Westlund, Erik, Mathioudakis, Nestoras, Zhang, Linying, Fan, Ruochong, Wilcox, Adam, Lai, Albert, Stocking, Jacqueline C, Xie, Yangyiran, Lee, Lok Hin, Dorr, David, Humes, Izabelle, McCoy, David, Adibuzzaman, Mohammad, Areaux, Raymond, Brash, James, Weiskopf, Nicole, Morgan-Cooper, Hannah, Desai, Priya, Tran, Diep, Rustam, Zainab, Zhu, Gina, Swerdel, Joel, Sena, Anthony, Nagy, Paul, Suchard, Marc, Schuemie, Martijn, Hripcsak, George, Ryan, Patrick
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England American Diabetes Association 04.11.2025 BMJ Publishing Group LTD BMJ Publishing Group
Predmet:	Aged Clinical medicine Clinical trials Diabetes Diabetes Complications Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Retinopathy Diabetic Retinopathy - chemically induced Diabetic Retinopathy - epidemiology Epidemiology/Health services research FDA approval Female Follow-Up Studies GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor Agonists Glucagon-Like Peptides - adverse effects Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - therapeutic use Hispanic Americans Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Informatics Male Middle Aged Peptides Retrospective Studies Sensitivity analysis Diabetes Complications Diabetic Retinopathy
ISSN:	2052-4897, 2052-4897
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	IntroductionSemaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications including proliferative DR (PDR) and diabetic macular edema (DME). The purpose of this study was to determine whether an association exists between semaglutide and PDR and treatment-requiring DR/DME.Research design and methodsThis was a retrospective cohort study of 14 databases (six administrative claims and eight electronic health records) in the Observational Health Data Sciences and Informatics Evidence Network. Adults with T2D on semaglutide, other GLP-1RA (dulaglutide, exenatide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The association between semaglutide and PDR or treatment-requiring DR/DME was assessed using an active-comparator cohort design comparing new users of semaglutide as second-line T2D treatment to those on other GLP-1RAs and non-GLP-1RAs. Propensity score-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs). Network-wide HR estimates were generated using a random-effects meta-analysis.ResultsThe study included 810 390 new semaglutide users for T2D. PDR risk for semaglutide was similar to dulaglutide (HR 0.81, 95% CI 0.42 to 1.54, p=0.51), empagliflozin (HR 0.83, 95% CI 0.53 to 1.30, p=0.41) and sitagliptin (HR 0.83, 95% CI 0.45 to 1.55, p=0.57) but was lower than glipizide (HR 0.59, 95% CI 0.39 to 0.88, p=0.01). The risk for treatment-requiring DR/DME for semaglutide was similar to empagliflozin (HR 0.66, 95% CI 0.43 to 1.02, p=0.06) but lower than dulaglutide (HR 0.53, 95% CI 0.31 to 0.91, p=0.02), sitagliptin (HR 0.46, 95% CI 0.26 to 0.81, p=0.008) and glipizide (HR 0.55, 95% CI 0.33 to 0.91, p=0.02).Conclusions and relevanceWe did not identify increased risk for either PDR or treatment-requiring DR/DME comparing semaglutide with other GLP-1RAs or non-GLP-1RAs. Patients with T2D should still undergo close eye care follow-up, particularly when initiating new antihyperglycemic medications.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	2052-4897 2052-4897
DOI:	10.1136/bmjdrc-2025-005424